Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
about
P1343
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerGaleterone for the treatment of advanced prostate cancer: the evidence to dateNew drugs in prostate cancerA sting in the tail: the N-terminal domain of the androgen receptor as a drug targetAndrogen Receptor Structure, Function and Biology: From Bench to BedsideResistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerSequence of treatment in locally advanced and metastatic renal cell carcinomaPersistent androgen receptor addiction in castration-resistant prostate cancerEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerTargeting Breast Cancer MetastasisUse of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancerTumour heterogeneity and the evolution of polyclonal drug resistanceQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesTargeting the adaptive molecular landscape of castration-resistant prostate cancerAR-V7 and resistance to enzalutamide and abiraterone in prostate cancerNovel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate CancerSelective glucocorticoid receptor-activating adjuvant therapy in cancer treatmentsUsing circulating tumor cells to inform on prostate cancer biology and clinical utilityDeciphering the divergent roles of progestogens in breast cancer.Prognostic Significance and Functional Role of CEP57 in Prostate CancerThe link between androgen receptor splice variants and castration-resistant prostate cancer.Computational identification of mutually exclusive transcriptional drivers dysregulating metastatic microRNAs in prostate cancerGlucocorticoids and prostate cancer treatment: friend or foe?Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Comparing the rules of engagement of androgen and glucocorticoid receptorsEnhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activationAndrogen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.Aggressive variants of castration-resistant prostate cancerNFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor HeterogeneityAgonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.Crystal structure of the mineralocorticoid receptor DNA binding domain in complex with DNA.PIP5K1α inhibition as a therapeutic strategy for prostate cancerDOT1L-HES6 fusion drives androgen independent growth in prostate cancerMolecular pathways and targets in prostate cancerThe emerging role of speckle-type POZ protein (SPOP) in cancer development.Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancerEnzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.
P2860
Q26739708-EBCDA019-FAF1-4EA7-96F9-9C6EEFD59F7EQ26739887-04E70C1A-548F-41AE-96F9-EF3915A1E435Q26745948-638E6CD1-D725-4A80-B684-497D349E432FQ26747094-292D7A38-64D7-47DB-A792-B6AE45E27113Q26750866-A7A5A7B3-01EB-4BE9-81B4-A72904CC7618Q26751237-874AE59F-0EAC-4288-AA50-820B55F19821Q26773653-58B7AFE2-B868-403B-9D0F-83697DCE93D1Q26777163-B8F38BAF-FAD9-489E-B8C9-FF2BC0ACF90AQ26777310-F91ECAAC-1A9C-4C3A-B6AC-D3D7FD971279Q26783925-EFF65DF6-0455-4818-9317-316EF2AD3A18Q26865701-060C0B27-A8D9-4DAE-BA53-4D30181E5EBDQ26866803-A34B6FD4-E0AF-4344-BB80-E838FF8DB8B6Q27011642-F1AACDD6-568E-44D8-8E4B-B2B6CE523149Q27022821-0F74BB3D-1FDF-452F-8871-5D56A1C264F4Q27853062-77EC5282-AA80-4A77-80AD-A470E506B36EQ28067556-2E212988-6409-411E-A965-260B219AE988Q28078896-A165B0D4-0B6B-45B1-B9CE-8C6DA37DEB75Q28083261-33A47E14-5327-4214-BC84-C7BE8AE6C4D8Q30240711-B7A50DFC-A23F-46F8-AC31-F1B93576FA59Q30361019-2F16779A-6A30-4D53-8652-507D0CED1294Q30618562-A9803B20-717D-40F1-8FA5-0F781173A126Q33571906-57A170E1-4F69-4310-9572-59B3B745E8C7Q33621387-AF9CA576-08CE-414B-864B-6E9D6079A053Q33621403-27DECE69-E4F9-4EB1-BA7F-B9665C16C045Q33658855-1FC971D4-AC74-48A3-B0C5-DBE5ACAF9B5CQ33665345-183ABE89-0100-4F96-B4BC-9D22F511301AQ33688956-CCC15AA5-67CB-49E4-A20D-3DE54EBDA6CBQ33693256-4C8C173F-1FD1-4EAA-A957-C408E7D44D71Q33701352-1E0E00A8-324C-488C-97AF-CC79A8FAE198Q33775717-75CFE112-29A2-458A-858E-CCBA33651785Q33883227-BD6D2D57-F8E9-436C-956E-3E1DB2751D6FQ34042831-1824D56D-7EC6-4F7B-AC8D-95D62173080FQ34134160-95092483-F0C2-40CF-B58F-50826A876524Q34144399-594FF0C7-5E5C-42D4-B340-B43524FE6C57Q34342466-C523B7FE-765F-48D7-B999-45020F3E2225Q34365632-FA6AE9AC-C20E-48AE-BB89-9FA26EC518B3Q34430637-FFE68E1B-7017-4903-A808-9DD9C3ECF26CQ34461177-645F8347-BE88-4FA4-88E6-135774BAA245Q34462138-02E6A7CB-77D2-4D59-B307-DAA5EA75DD08Q34464312-11BD21BF-4DDC-4D04-811A-678E9CBA8C7F
P2860
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Glucocorticoid receptor confer ...... ng androgen receptor blockade.
@ast
Glucocorticoid receptor confer ...... ng androgen receptor blockade.
@en
Glucocorticoid receptor confer ...... ng androgen receptor blockade.
@nl
type
label
Glucocorticoid receptor confer ...... ng androgen receptor blockade.
@ast
Glucocorticoid receptor confer ...... ng androgen receptor blockade.
@en
Glucocorticoid receptor confer ...... ng androgen receptor blockade.
@nl
prefLabel
Glucocorticoid receptor confer ...... ng androgen receptor blockade.
@ast
Glucocorticoid receptor confer ...... ng androgen receptor blockade.
@en
Glucocorticoid receptor confer ...... ng androgen receptor blockade.
@nl
P2093
P2860
P1433
P1476
Glucocorticoid receptor confer ...... ng androgen receptor blockade.
@en
P2093
Charles L Sawyers
Chris Logothetis
Eleni Efstathiou
Emily Schenkein
John Wongvipat
Minna D Balbas
Sumit K Subudhi
Vivek K Arora
P2860
P304
P356
10.1016/J.CELL.2013.11.012
P407
P577
2013-12-01T00:00:00Z